Miss Raffaella Casolino
- Affiliate (School of Cancer Sciences)
email:
Raffaella.Casolino@glasgow.ac.uk
Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre
The University of Glasgow uses cookies for analytics and advertising. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Hotjar helps us to understand and improve our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
email:
Raffaella.Casolino@glasgow.ac.uk
Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre
Casolino, R., Corbo, V., Beer, P., Hwang, C.-I., Paiella, S., Silvestri, V., Ottini, L. and Biankin, A. V. (2022) Germline aberrations in pancreatic cancer: implications for clinical care. Cancers, 14(13), 3239. (doi: 10.3390/cancers14133239) (PMID:35805011) (PMCID:PMC9265115)
Casolino, R., Amato, F., Rae, C. , Puttagunta, S. and Braconi, C. (2022) Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers. Journal of Hepatology, 76(5), pp. 1227-1229. (doi: 10.1016/j.jhep.2022.01.012) (PMID:35093472)
Casolino, R. et al. (2021) Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. Journal of Clinical Oncology, 39(23), pp. 2617-2631. (doi: 10.1200/JCO.20.03238) (PMID:34197182) (PMCID:PMC8331063)
Casolino, R. et al. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32(2), pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013) (PMID:33248227) (PMCID:PMC7840891)
Froeling, F. E.M. , Casolino, R., Pea, A., Biankin, A. V. and Chang, D. K. (2021) Molecular subtyping and precision medicine for pancreatic cancer. Journal of Clinical Medicine, 10(1), 149. (doi: 10.3390/jcm10010149) (PMID:33406790) (PMCID:PMC7794969)
Casolino, R., Corbo, V., Beer, P., Hwang, C.-I., Paiella, S., Silvestri, V., Ottini, L. and Biankin, A. V. (2022) Germline aberrations in pancreatic cancer: implications for clinical care. Cancers, 14(13), 3239. (doi: 10.3390/cancers14133239) (PMID:35805011) (PMCID:PMC9265115)
Casolino, R., Amato, F., Rae, C. , Puttagunta, S. and Braconi, C. (2022) Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers. Journal of Hepatology, 76(5), pp. 1227-1229. (doi: 10.1016/j.jhep.2022.01.012) (PMID:35093472)
Casolino, R. et al. (2021) Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. Journal of Clinical Oncology, 39(23), pp. 2617-2631. (doi: 10.1200/JCO.20.03238) (PMID:34197182) (PMCID:PMC8331063)
Casolino, R. et al. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32(2), pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013) (PMID:33248227) (PMCID:PMC7840891)
Froeling, F. E.M. , Casolino, R., Pea, A., Biankin, A. V. and Chang, D. K. (2021) Molecular subtyping and precision medicine for pancreatic cancer. Journal of Clinical Medicine, 10(1), 149. (doi: 10.3390/jcm10010149) (PMID:33406790) (PMCID:PMC7794969)